Could Synchron IPO Before Neuralink in 2027?

Synchron's private valuation has climbed to approximately $1.5 billion following its Series C funding round, positioning the endovascular BCI company as a potential first-mover in public markets. The Brooklyn-based company, which has implanted its Stentrode device in 10 patients across US and Australian trials, is reportedly considering an IPO timeline for late 2027 or early 2028, according to sources familiar with the company's strategic planning.

Unlike competitors requiring craniotomy procedures, Synchron's minimally invasive approach threads its 16-electrode Stentrode through blood vessels to reach the motor cortex. This differentiated surgical pathway has enabled faster patient enrollment and potentially broader addressable markets compared to intracortical alternatives. The company's COMMAND trial (NCT03834857) demonstrated sustained signal quality at 12 months, with patients achieving cursor control and text input capabilities reaching 25 characters per minute.

Market dynamics favor Synchron's public debut timing. While Neuralink Corp generates headlines with its N1 implant's high bandwidth capabilities, regulatory timelines suggest Synchron could reach commercialization first. The company received FDA Breakthrough Device Designation in 2020 and is advancing toward pivotal trials, while maintaining a cleaner regulatory profile without the animal welfare scrutiny facing competitors.

Market Position and Competitive Landscape

Synchron has carved out a unique position in the BCI market by focusing on patients with severe paralysis, particularly those with Amyotrophic Lateral Sclerosis (ALS) and stroke. The company's endovascular approach addresses a critical limitation in BCI adoption: surgical risk tolerance among patients and physicians.

The Stentrode's placement in the superior sagittal sinus provides access to motor cortical signals without penetrating brain tissue. While this positioning limits bandwidth compared to intracortical arrays—Synchron achieves approximately 2-4 bits per second versus Neuralink's reported 8+ bps—it offers significant advantages in safety profile and surgical accessibility.

Recent patient outcomes from Synchron's ongoing trials demonstrate practical utility despite lower bandwidth. Patients have successfully controlled smart home devices, sent emails, and operated computer interfaces using only neural signals. One patient, a 62-year-old male with ALS, maintained consistent device performance for over 18 months post-implantation.

Precision Neuroscience represents Synchron's closest competitor in terms of surgical approach, though their Layer 7 Cortical Interface requires craniotomy with subdural placement. Blackrock Neurotech continues advancing their NeuroPort arrays but faces similar invasiveness challenges.

Financial Trajectory and IPO Readiness

Synchron's path to public markets reflects careful capital management and strategic milestone achievement. The company has raised approximately $145 million across multiple funding rounds, with participation from Khosla Ventures, Forepont Capital Partners, and Gates Frontier. This relatively modest funding compared to competitors suggests efficient capital deployment and lower cash burn rates.

Revenue generation remains limited to clinical trial partnerships and research collaborations, typical for pre-commercial BCI companies. However, Synchron's regulatory pathway appears more predictable than competitors, potentially enabling faster time-to-revenue following FDA approval.

The company's intellectual property portfolio includes over 100 patents covering endovascular neural interfaces, signal processing algorithms, and implant designs. This IP moat provides defensive positioning against larger medical device incumbents who might seek to enter the BCI space through acquisition or internal development.

Market appetite for neurotechnology IPOs remains untested, though medical device investors have shown increased interest following successful outcomes from neuromodulation companies like Nevro Corporation. Synchron's approach of targeting established neurosurgical workflows rather than requiring new surgical subspecialties could appeal to institutional investors seeking lower adoption risk profiles.

Regulatory Pathway and Commercial Prospects

Synchron's FDA strategy emphasizes safety and reliability over maximum performance, a positioning that may accelerate approval timelines. The company's IDE studies have demonstrated acceptable safety profiles with no device-related serious adverse events reported in published data.

The SWITCH trial represents Synchron's largest clinical effort, enrolling patients across multiple centers to demonstrate the Stentrode's utility in restoration of digital device control. Early results suggest the company could file for FDA approval by late 2026, with potential commercial launch in 2028-2029.

Reimbursement strategy remains a critical factor for commercial success. Synchron has engaged with CMS and private payers to establish appropriate coding and coverage pathways. The company's positioning of BCI therapy as assistive technology rather than experimental intervention could facilitate insurance coverage decisions.

Competition from established medical device companies represents a longer-term risk. Medtronic's acquisition of Mazor Robotics and Abbott's investments in neurostimulation suggest large-cap medical device companies are monitoring BCI development closely.

Key Takeaways

• Synchron's $1.5B valuation reflects strong positioning in endovascular BCI market segment
• Company's minimally invasive approach enables faster clinical enrollment and broader patient accessibility
• IPO timeline of late 2027/early 2028 could make Synchron the first pure-play BCI public company
• Regulatory pathway appears more predictable than intracortical competitors requiring craniotomy
• Revenue generation limited until FDA approval, expected 2028-2029

Frequently Asked Questions

What makes Synchron's approach different from other BCI companies? Synchron uses an endovascular approach, inserting its Stentrode device through blood vessels rather than requiring open brain surgery. This minimally invasive method reduces surgical risk while maintaining access to motor cortical signals.

When could Synchron go public? Industry sources suggest Synchron is considering an IPO timeline for late 2027 or early 2028, contingent on regulatory progress and market conditions. This timing could position Synchron as the first pure-play BCI company to go public.

How does Synchron's bandwidth compare to competitors? Synchron achieves 2-4 bits per second of information transfer, lower than intracortical systems like Neuralink's N1 implant. However, this bandwidth has proven sufficient for practical applications like cursor control and text input in clinical trials.

What is Synchron's current valuation? Synchron's private valuation has reached approximately $1.5 billion following its most recent funding round, making it one of the highest-valued BCI companies currently in private markets.

Who are Synchron's main competitors? Primary competitors include Neuralink, Precision Neuroscience, and Blackrock Neurotech. Synchron differentiates through its endovascular approach, while competitors primarily use intracortical or surface-based electrode placement requiring more invasive surgical procedures.